Search for dissertations about: "Henrik Riska"

Found 3 swedish dissertations containing the words Henrik Riska.

  2. 1. Prognostic Factors in Non-Small Cell Lung Cancer (NSCLC)

    Author : Georg Holgersson; Stefan Bergström; Michael Bergqvist; Simon Ekman; Fredrik Pontén; Henrik Riska; Uppsala universitet; []
    Keywords : NSCLC; prognostic factors; survival; histology; anemia; leukocytosis; thrombocytosis; Oncology; Onkologi;

    Abstract : Background: Non-small cell lung cancer (NSCLC) is the cancer disease with the highest mortality globally. About 75% of NSCLC patients are diagnosed in an advanced stage where surgical treatment is not possible. For patients with locally advanced disease without distant metastases, the treatment of choice is curatively intended radiotherapy. READ MORE

  4. 2. Clinical Aspects of Inflammation in Non-small Cell Lung Cancer

    Author : Andrea Koch; Sverre Sörenson; Birgitta Clinchy; Bengt Bergman; Henrik Riska; Linköpings universitet; []
    Keywords : MEDICINE; MEDICIN;

    Abstract : Lung cancer is the most common cause of cancer death worldwide, with about 1.2 million deaths every year. In Sweden, about 3500 new cases are diagnosed every year. The majority of patients presents with advanced non-small cell lung cancer (NSCLC) and is treated with palliative intent. READ MORE

  5. 3. Prognosis, Prediction and Risk Assessment in the Prevention and Treatment of Non-Small Cell Lung Cancer

    Author : Martin Sandelin; Christer Janson; Henrik Riska; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; chemoradiation therapy; induction chemotherapy; thrombocytosis; anaemia; leucocytosis; EGFR; guidelines; molecular pathology; ACOS; COPD; risk assessment; comorbidities; Lung Medicine; Lungmedicin;

    Abstract : Background: Lung cancer causes more deaths than any other cancer. Smoking causes roughly 90% of lung cancer cases. Concurrent chemoradiation therapy is the standard of care for stage IIIb patients with performance status (PS) 0-1. A less toxic approach is warranted for less fit patients. READ MORE